Date:2/24/2009

2007 ---- ---- Net cash provided by operating activities $91,437 $122,867 Net cash provided by (used in) Investing activities 15,440 (216,176) Net cash (used in)/provided by financing activities (10,070) 221,471 Selected Consolidated Balance Sheet Data December 31, December 31, (in thousands) 2008 2007 ---- ---- Assets Current assets: Cash and cash equivalents $275,839 $179,691 Short-term investments - 404,637 Deferred income taxes 26,785 7,983 Total current assets 356,445 622,773 Intangible assets, net 639,693 122,502 Goodwill 34,787 - Deferred income taxes 91,757 12,312 Total assets 1,147,574 776,066 Liabilities and Stockholders' Equity Total current liabilities $51,086 $28,370 Deferred tax liabilities 181,392 - Long-term debt 250,000 250,000 Total liabilities 486,550 279,503 Total stockholders' equity 661,024 496,563 Total liabilities and stockholders' equity 1,147,574 776,066

'/>"/>

SOURCE ViroPharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference